InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
Go back to InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum| InferX Corporation (NASDAQ: IFRX) | Delayed: 1.55 +0.01 (0.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.54 | 52 Week High | $0.05 | |||
| Open | $1.55 | 52 Week Low | $0.00 | |||
| Day High | $1.61 | P/E | N/A | |||
| Day Low | $1.54 | EPS | $0.00 | |||
| Volume | 701,424 | |||||



